Drug Profile
Setipiprant - Actelion Pharmaceuticals / Kythera Biopharmaceuticals
Alternative Names: ACT-129968; KYTH-105Latest Information Update: 15 Apr 2021
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Developer Actelion Pharmaceuticals; Kythera Biopharmaceuticals
- Class Acetic acids; Antiallergics; Antiasthmatics; Fluorinated hydrocarbons; Indoles; Naphthalenes; Pyridones; Skin disorder therapies; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alopecia; Asthma; Seasonal allergic rhinitis
Most Recent Events
- 15 Apr 2021 Discontinued - Phase-II for Alopecia in USA (PO) before April 2021 (Abbvie pipeline, April 2021)
- 22 May 2018 Allergan completes a phase II trial in Alopecia in USA (PO) (NCT02781311)
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals